Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation

NCT05691465 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05691465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05691465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Lutetium Lu 177 Dotatate in Metastatic Prostate Cancer With Neuroendocrine Differentiation
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
December 27, 2023
Completion date
June 1, 2027
Enrollment
35 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic prostate adenocarcinoma with neuroendocrine differentiation, metastatic prostate neuroendocrine carcinoma, metastatic prostate small cell neuroendocrine carcinoma, stage ivb prostate cancer ajcc v8